Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Interleukin-2 (IL-2) & Renal Cell Carcinoma (RCC)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Regulatory status

In the context of Interleukin-2 (IL-2) & Renal Cell Carcinoma (RCC), interleukin‑2 is FDA‑ and EMA‑aligned (via national/EU‑level approvals) for renal cell carcinoma, specifically for metastatic disease, but it is used in only a small subset of patients today due to toxicity and the availability of newer therapies (1, 2, 3, 4)

References

(1) Amin & White 2014 J Kidney Cancer VHL 1(7): 74-83
(2) Rosenberg 2007 Nat Clin Pract Oncol 4(9): 497
(3) McDermott & Atkins 2006 Semin Oncol 33(5): 583-7
(4) Hemminki et al. 2020 Eur Urol Open Sci 22: 61-73

…

References (Sources)

Interleukin 2 for patients with renal cancer
Rosenberg 2007 Nat Clin Pract Oncol 4(9): 497
Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option?
Amin & White 2014 J Kidney Cancer VHL 1(7): 74-83
Review
Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response
McDermott & Atkins 2006 Semin Oncol 33(5): 583-7
Review
Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not
Hemminki et al. 2020 Eur Urol Open Sci 22: 61-73
Review

AI Chat

7/2/2026

Chat with our artificial intelligence:

Start chat!